- Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
-
Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ
- KMID: 1712743
- J Korean Med Sci.
- 2005 Aug;20(4):618-623.
- doi: 10.3346/jkms.2005.20.4.618
Although various combinations of chemotherapy regimens have been tried for patients with esophageal cancer, their duration of survival is extremely poor. In this study, we investigated the safety and clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions
-
Maurer K, Michener C, Mahdi H, Rose PG
- KMID: 2413426
- J Gynecol Oncol.
- 2017 Jul;28(4):e38.
- doi: 10.3802/jgo.2017.28.e38
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy... -
- CITED
-
- Close
- SHARE
-
- Close
- Utility of ELISA Optical Density Values and Clinical Scores for the Diagnosis of and Thrombosis Prediction in Heparin-induced Thrombocytopenia
-
Kim SY, Kim HK, Han KS, Kim I, Yoon SS, Park S, Kim BK
- KMID: 1096652
- Korean J Lab Med.
- 2011 Jan;31(1):1-8.
- doi: 10.3343/kjlm.2011.31.1.1
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction caused by antibodies to the heparin/platelet factor 4 (PF4) complex, resulting in thrombocytopenia and prothrombotic state. HIT diagnosis is challenging and... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy
-
Hwang JJ, Lo CC, Lin CH, Cheng HS, Hung IW, Tsai WJ, Hung CH
- KMID: 2380767
- Gut Liver.
- 2015 Mar;9(2):214-223.
- doi: 10.5009/gnl14095
BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect... -
- CITED
-
- Close
- SHARE
-
- Close
- A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
-
Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, Lee JH, Lee ST, Kim JH, Yoon SS, Lee JS, Park S, Kim BK, Kim NK
- KMID: 1712739
- J Korean Med Sci.
- 2005 Aug;20(4):598-602.
- doi: 10.3346/jkms.2005.20.4.598
Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We... -
- CITED
-
- Close
- SHARE
-
- Close
